PRESS RELEASE published on 05/02/2024 at 12:30, 2 years 6 months ago Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024 Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula
BRIEF published on 04/25/2024 at 13:05, 2 years 6 months ago Moderna to Present Diverse Research Studies at ESCMID Global Congress COVID-19 Vaccine Moderna Vaccine Research Influenza Vaccine ESCMID Congress
BRIEF published on 04/25/2024 at 13:05, 2 years 6 months ago Moderna présentera diverses études de recherche au congrès mondial ESCMID Recherche Sur Les Vaccins Moderne Vaccin Contre Le Covid-19 Vaccin Contre La Grippe Congrès ESCMID
PRESS RELEASE published on 04/25/2024 at 13:00, 2 years 6 months ago Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress Moderna, Inc. to present data on COVID-19, influenza, respiratory syncytial virus, and cytomegalovirus vaccines at ESCMID Global Congress in Barcelona, Spain COVID-19 Moderna Inc. Barcelona Vaccines ESCMID Global Congress
BRIEF published on 04/24/2024 at 14:05, 2 years 6 months ago Moderna Collaborates with OpenAI to Enhance mRNA Medicines Using Advanced AI Healthcare Innovation MRNA Technology Moderna OpenAI AI Collaboration
BRIEF published on 04/24/2024 at 14:05, 2 years 6 months ago Moderna collabore avec OpenAI pour améliorer les médicaments à ARNm grâce à l'IA avancée Technologie ARNm Innovation En Matière De Soins De Santé Moderne OpenAI Collaboration IA
PRESS RELEASE published on 04/24/2024 at 14:00, 2 years 6 months ago Moderna and OpenAI Collaborate To Advance mRNA Medicine Moderna and OpenAI collaborate to integrate generative AI tools, like ChatGPT Enterprise, into operations to enhance AI culture and augment employee roles for maximum impact on patients Generative AI Machine Learning Moderna OpenAI ChatGPT Enterprise
BRIEF published on 04/17/2024 at 13:05, 2 years 6 months ago Moderna to Present Q1 2024 Financial Results in May Financial Results Conference Call Webcast Moderna Q1 2024
BRIEF published on 04/17/2024 at 13:05, 2 years 6 months ago Moderna présentera ses résultats financiers du premier trimestre 2024 en mai Résultats Financiers Webdiffusion Conférence Téléphonique Moderne T1 2024
PRESS RELEASE published on 04/17/2024 at 13:00, 2 years 6 months ago Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 Moderna, Inc. will host a live conference call to report Q1 2024 financial results and provide a corporate update. Moderna is a leader in mRNA medicine revolutionizing disease treatment Financial Results Conference Call Corporate Update Moderna Inc. MRNA Medicine
Published on 11/10/2026 at 14:31, 21 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 22 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:00, 52 minutes ago Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Published on 11/10/2026 at 14:46, 6 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 11/10/2026 at 14:35, 17 minutes ago K-Beauty at CES: Kolmar Korea Becomes First Company to Win Best of Innovation in Beauty Tech Two Years in a Row
Published on 11/10/2026 at 14:35, 17 minutes ago XLIO Secures Additional $100 Million to Build Startups for Corporate Acquirers
Published on 11/10/2026 at 14:00, 52 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 2 au 6 novembre 2026
Published on 11/10/2026 at 14:00, 52 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 2 to November 6, 2026
Published on 11/10/2026 at 11:02, 3 hours 49 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 11:02, 3 hours 49 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Published on 11/10/2026 at 07:00, 7 hours 52 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
